Suki has announced $90 million in financing as part of its Series E, with the healthcare AI company planning to expand its technology, software integrations and commercial operations. The October 13 announcement names Healthier Capital, Crosslink Capital and Hercules Capital as new investors. Existing institutional backers also participated. Healthier Capital partner Aman Mahajan will join Suki's board.
The Redwood City, California company sells an application for clinicians and supplies technology that other healthcare software companies embed in their products. Suki says it serves more than 450 healthcare organisations and works with more than 30 technology partners. The financing backs its push beyond medical notes into clinical, financial and operational work. The release does not disclose a valuation or divide the financing into equity and debt. Its customer counts are company-reported.
From medical notes to clinical queries
That expansion is already taking shape through Ask, launched on October 8 across Epic, Oracle Health, athenahealth and MEDITECH. Within Suki for Clinicians, doctors can type or speak questions to retrieve information from a patient's electronic record, including medicines, allergies and laboratory results. For clinicians with UpToDate access, the integration also returns answers grounded in Wolters Kluwer's clinical reference content. Responses link to supporting evidence, letting the clinician inspect the material behind an answer without leaving the same workflow. Suki says Ask is available on mobile and desktop, and through a Chrome extension, as well as inside Epic.
Suki's product explanation sets a boundary around that capability: Ask retrieves and combines information, but does not make medical diagnoses or prescribe treatment plans. Clinicians remain responsible for reviewing the output and deciding on care. The company says it plans to add other clinical sources, including guidelines and calculators, and more agents for completing tasks. These are stated development plans. The product explanation gives no delivery date for those additions, and the October 8 material does not establish that the tool improves patient outcomes.
What deployment evidence shows
Evidence about the company's earlier documentation work is more developed. A McLeod Health study published on June 26 describes a three-month pilot that began in October 2024. Of 49 clinicians onboarded, data from 23 met the criteria for analysis. Among these active users, median note-writing time per appointment fell by 28.3%, a statistically significant result. After-hours work fell by 35.4%, but that result did not reach the study's conventional statistical threshold. Same-day note closure did not change significantly. The findings concern the earlier documentation deployment and do not test the Ask feature.
The study also explains the commercial arrangement behind the wider rollout. McLeod negotiated usage-based pricing with a monthly cap to limit the cost of unused licences, then opened access more widely. Its authors reported no external study funding, while disclosing that one author was invited to the vendor's advisory board after submission. There was no concurrent control group, and the analysis did not assess total ownership costs. Those limits matter when interpreting the results as evidence for purchasing or scaling software across a health system.
A separate research partnership announced on September 17 gives Suki another route to test how its software is used. MedStar Health's National Center for Human Factors in Healthcare will study deployment across MedStar clinical sites. The work includes designing and testing interventions to improve adoption, rather than assuming every clinician will use the software in the same way. Researchers will also examine administrative workload, clinical reasoning and the experience of patients, clinicians and trainees across different care settings.
The collaboration includes evaluating safety and care quality within clinical workflows. It will combine quantitative and qualitative research, with findings intended for submission to scientific publications and wider sharing. The announcement sets out a research programme, not completed results, and gives no publication deadline. Alongside the earlier McLeod study, it identifies the evidence still being assembled as Suki seeks broader hospital use. Joshua Biro, a research scientist at the centre, is the partnership's principal investigator. Suki's Sudha Jayaraman leads its contribution to the collaboration.
Dalimss News has also covered Prodoc AI's seed funding for hospital software and Kardi Ai's India entry in ECG monitoring, separate developments in healthcare technology.
